[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR102222A1 - Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos - Google Patents

Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos

Info

Publication number
AR102222A1
AR102222A1 ARP150103264A ARP150103264A AR102222A1 AR 102222 A1 AR102222 A1 AR 102222A1 AR P150103264 A ARP150103264 A AR P150103264A AR P150103264 A ARP150103264 A AR P150103264A AR 102222 A1 AR102222 A1 AR 102222A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
independently selected
indolinona
compounds
Prior art date
Application number
ARP150103264A
Other languages
English (en)
Inventor
Vernier Jean
Michel
Original Assignee
Tokalas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokalas Inc filed Critical Tokalas Inc
Publication of AR102222A1 publication Critical patent/AR102222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un compuesto que tiene una estructura de la fórmula (1), o un estereoisómero, una sal farmacéuticamente aceptable o solvato del mismo, donde R¹, R², R³, y R⁴ se seleccionan independientemente del grupo que consiste en H, Cl, -CN Y -CF₃; donde A se selecciona del grupo que consiste en H y alquilo C₁₋₆; donde D se selecciona del grupo que consiste en -OH y -O(alquilo C₁₋₆); donde R⁵ y R⁶ se seleccionan independientemente del grupo que consiste en H, F y alquilo C₁₋₆, o donde R⁵ y R⁶ tomados en conjunto forman un anillo de cicloalquilo sustituido o insustituido; donde R¹² se selecciona independientemente del grupo que consiste en cicloalquilo C₃₋₈ y un resto de fórmula (2); donde R⁷, R⁸, R⁹, R¹⁰ y R¹¹ se seleccionan independientemente del grupo que consiste en H, halógeno, CN, CF₃, alquilo C₁₋₆, arilo, heteroarilo, -O(arilo), -O(heteroarilo), -CO₂H, -CO₂(alquilo C₁₋₆), -NHSO₂(alquilo C₁₋₆), -NHSO₂(arilo), -NHCONH(alquilo C₁₋₆), -NHCON(alquilo C₁₋₆)₂, -N(alquilo C₁₋₆)CONH₂, -N(alquilo C₁₋₆)CONH(alquilo C₁₋₆), -N(alquilo C₁₋₆)CON(alquilo C₁₋₆)₂, -SO₂(alquilo C₁₋₆), -SO₂NH₂, -SO₂NH(alquilo C₁₋₆), -SO₂N(alquilo C₁₋₆)₂, cicloalquilo C₃₋₈ y heterocicloalquilo C₃₋₈.
ARP150103264A 2014-10-09 2015-10-09 Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos AR102222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462062086P 2014-10-09 2014-10-09

Publications (1)

Publication Number Publication Date
AR102222A1 true AR102222A1 (es) 2017-02-15

Family

ID=54337916

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103264A AR102222A1 (es) 2014-10-09 2015-10-09 Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos

Country Status (14)

Country Link
US (5) US9604927B2 (es)
EP (1) EP3204376B1 (es)
JP (2) JP6654197B2 (es)
KR (1) KR102482197B1 (es)
CN (2) CN111777596A (es)
AR (1) AR102222A1 (es)
AU (2) AU2015328121B2 (es)
CA (1) CA2961781C (es)
EA (1) EA032644B1 (es)
IL (2) IL251498B (es)
MX (1) MX2017003589A (es)
NZ (1) NZ730585A (es)
TW (2) TWI705054B (es)
WO (1) WO2016057698A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836481B1 (en) 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
EA032644B1 (ru) * 2014-10-09 2019-06-28 Онктернал Терапьютикс, Инк. Производные индолинона и их применение
EP3436434B1 (en) * 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
US10159660B2 (en) * 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
CN110818611B (zh) * 2018-08-13 2023-01-24 中国科学院上海药物研究所 一类吲哚酮类化合物、其制备方法、药物组合物和用途
WO2022060856A2 (en) * 2020-09-17 2022-03-24 Oklahoma Medical Research Foundation Inhibition of endothelial ets family transcription factors promotes flow-dependent ocular vessel regression
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU583793B2 (en) 1983-07-22 1989-05-11 Du Pont Pharmaceuticals Company Phenylquinolinecarboxylic acids and derivatives as antitumor agents
WO2000033834A1 (en) 1998-12-04 2000-06-15 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
EP3034510A1 (en) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20090217390A1 (en) 2005-04-29 2009-08-27 Fernando Lecanda Cordero Non-human animal sarcoma model
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
WO2008083326A2 (en) 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
PT2154966E (pt) 2007-04-20 2013-11-13 Univ New York State Res Found Benzimidazóis e suas composições farmacêuticas
US8377992B2 (en) 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
EP3401684B1 (en) * 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
WO2010083505A1 (en) * 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
WO2012078519A2 (en) * 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
CN102516152B (zh) 2011-12-12 2014-12-10 华东师范大学 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
WO2013151981A1 (en) 2012-04-02 2013-10-10 Gradalis, Inc. Ewing's sarcoma bifunctional shrna design
EP2836481B1 (en) * 2012-04-12 2018-12-26 Georgetown University Compounds and compositions for treating ewings sarcoma family of tumors
MX2015000804A (es) 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
AU2014244083B2 (en) * 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
CN103435606A (zh) * 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
JP6389884B2 (ja) 2013-10-24 2018-09-12 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ 癌を治療するための方法及び組成物
KR101813830B1 (ko) 2013-12-05 2017-12-29 에프. 호프만-라 로슈 아게 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
EA032644B1 (ru) 2014-10-09 2019-06-28 Онктернал Терапьютикс, Инк. Производные индолинона и их применение
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
US10159660B2 (en) * 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds

Also Published As

Publication number Publication date
EP3204376B1 (en) 2023-04-19
US9604927B2 (en) 2017-03-28
US20220288023A1 (en) 2022-09-15
IL284322B2 (en) 2023-08-01
CN107108580B (zh) 2020-06-30
TWI705054B (zh) 2020-09-21
AU2020200631A1 (en) 2020-02-20
IL284322B1 (en) 2023-04-01
US20170066720A1 (en) 2017-03-09
AU2015328121B2 (en) 2019-11-21
CN111777596A (zh) 2020-10-16
JP2020059736A (ja) 2020-04-16
IL251498B (en) 2021-07-29
KR102482197B1 (ko) 2022-12-27
IL284322A (en) 2021-07-29
US9895352B2 (en) 2018-02-20
AU2015328121A1 (en) 2017-04-06
CA2961781A1 (en) 2016-04-14
MX2017003589A (es) 2018-08-15
NZ730585A (en) 2018-08-31
AU2020200631B2 (en) 2022-03-24
CN107108580A (zh) 2017-08-29
EA032644B1 (ru) 2019-06-28
TW201629013A (zh) 2016-08-16
KR20170066609A (ko) 2017-06-14
US20170065559A1 (en) 2017-03-09
TWI750782B (zh) 2021-12-21
JP6795861B2 (ja) 2020-12-02
CA2961781C (en) 2023-10-03
US20180256546A1 (en) 2018-09-13
JP2017532377A (ja) 2017-11-02
WO2016057698A1 (en) 2016-04-14
EP3204376A1 (en) 2017-08-16
US9987251B2 (en) 2018-06-05
JP6654197B2 (ja) 2020-02-26
IL251498A0 (en) 2017-05-29
US20160102055A1 (en) 2016-04-14
EA201790445A1 (ru) 2017-09-29
TW202114986A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
AR102222A1 (es) Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
AR110922A1 (es) Compuestos inhibidores del vih
AR103252A1 (es) Compuestos de quinazolina
AR108010A1 (es) Derivados de indolina y su uso como inhibidores de ews-fli1
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR092306A1 (es) Antibacterianos de fenicol
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR108387A1 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR106604A1 (es) Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR108864A1 (es) Agentes antibacterianos
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR109776A1 (es) Compuestos de p2x₃ y/o p2x₂/₃ y métodos
AR108175A1 (es) Compuestos antivíricos de tiazol acetamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure